September 21, 2014 7:51 PM ET

Pharmaceuticals

Company Overview of Mallinckrodt LLC

Company Overview

Mallinckrodt LLC manufactures and distributes products used in diagnostic procedures, and in the treatment of pain and related conditions. It offers addiction treatment products, and specialty generics and pharmaceuticals; and active pharmaceutical ingredients, including medicinal narcotics, acetaminophen/paracetamol, stearates, phosphates, and peptides, as well as analytical research samples for pharmaceutical companies and analytical laboratories. The company also supplies medical isotope technetium-99m; and radiopharmaceuticals, and contrast media and delivery systems. It serves customers in the United States and internationally. The company was founded in 1867 and is based in St. Louis, ...

675 McDonnell Boulevard

St. Louis, MO 63042

United States

Founded in 1867

12,265 Employees

Phone:

314-654-2000

Fax:

314-654-6511

Key Executives for Mallinckrodt LLC

Mallinckrodt LLC does not have any Key Executives recorded.

Mallinckrodt LLC Key Developments

Nuvo Research Inc. Enters into Settlement Agreement with Mallinckrodt Inc

Nuvo Research Inc. has entered into a settlement agreement with Mallinckrodt Inc. for a litigation relating to Nuvo's license to Mallinckrodt of the right to market and sell Pennsaid and Pennsaid 2% in the US. Under the terms of the settlement agreement, Mallinckrodt will return all US rights to Pennsaid and Pennsaid 2% to Nuvo after a brief transition period and pay USD 10 million. Pennsaid is used to treat the signs and symptoms associated with knee osteoarthritis (OA). The drug combines the transdermal carrier (containing dimethyl sulfoxide, popularly known as DMSO) with 1.5% diclofenac sodium, a non-steroidal anti-inflammatory drug (NSAID) and delivers the active drug through the skin directly to the site of inflammation and pain. Pennsaid is currently marketed in the US by Mallinckrodt, in Canada by Paladin Labs Inc. and marketed under license and/or distribution agreements in Greece, Italy and the UK.

IGI, Laboratories, Inc. Enters into Non-Exclusive License with Mallinckrodt LLC and Nuvo Research Inc

IGI Laboratories Inc. announced that it has entered into an agreement with Mallinckrodt LLC, Mallinckrodt Inc., and Nuvo Research Inc. to settle a declaratory judgment action brought by IGI, concerning IGI's filing of an abbreviated new drug application with the U.S. Food and Drug Administration seeking approval to market a generic version of PENNSAID (diclofenac sodium topical solution) 1.5% w/w. Under the terms of this agreement, Mallinckrodt granted IGI a non-exclusive license to launch its diclofenac sodium topical solution 1.5% product on March 28, 2015. IGI received tentative approval of its diclofenac sodium topical solution 1.5% from the FDA on May 7, 2014.

Mallinckrodt Pharmaceuticals Presents at ChinaBio(R) Partnering Forum 2014, May-07-2014 04:45 PM

Mallinckrodt Pharmaceuticals Presents at ChinaBio(R) Partnering Forum 2014, May-07-2014 04:45 PM. Venue: Kempinski Hotel Suzhou, Suzhou, China.

Similar Private Companies By Industry

Company Name Region
Intendis, Inc. United States
Natural Planet USA, Inc. United States
Locus Pharmaceuticals, Inc. United States
BIOVIRx, Inc. United States
CannaPharmaRX, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Mallinckrodt LLC, please visit www.mallinckrodt.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.